Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

NCT02600455 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 505

Last updated 2017-01-13

No results posted yet for this study

Summary

The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.

Conditions

Interventions

DRUG

Orencia

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Japan

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600455 on ClinicalTrials.gov